Divya Ramakrishnan

Divya Ramakrishnan

Auto-generated profile, based on publicly available information

Divya Ramakrishnan

Department of Radiology and Biomedical Imaging, Yale School of Medicine , New Haven, Connecticut , USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DHDaphne A. Haas-Kogan
Daphne A. Haas-Kogan
MAMariam S. Aboian
Mariam S. Aboian
JMJane E. Minturn
Jane E. Minturn
SLSarah E.S. Leary
Sarah E.S. Leary
MAMohamed S. Abdelbaki
Mohamed S. Abdelbaki
SMSabine Mueller
Sabine Mueller
PURPOSE: The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers. PATIENTS AND METHODS: Patients, age 3-21 years, with progressive/recurrent pLGG received everolimus orally, 5 mg/m2 once daily. Frequency of driver gene alterations was compared among independent pLGG cohorts of newly diagnosed and progressive/recurrent patients. PFS at 6 months (primary end point) and median PFS (secondary end point) were estimated for association with everolimus therapy. RESULTS: Between 2012 and 2019, 65 subjects with progressive/recurrent pLGG (median age, 9.6 years; range, 3.0-19.9; 46% female) were enrolled, with a median follow-up of 57.5 months. The 6-month PFS was 67.4% (95% CI, 60.0 to 80.0) and median PFS was 11.1 months (95% CI, 7.6 to 19.8). Hypertriglyceridemia was the most common grade ≥3 adverse event. PI3K/AKT/mTOR pathway activation did not correlate with clinical outcomes (6-month PFS, active 68.4% v nonactive 63.3%; median PFS, active 11.2 months v nonactive 11.1 months; P = .80). Rare/novel KIAA1549::BRAF fusion breakpoints were most frequent in supratentorial midline pilocytic astrocytomas, in patients with progressive/recurrent disease, and correlated with poor clinical outcomes (median PFS, rare/novel KIAA1549::BRAF fusion breakpoints 6.1 months v common KIAA1549::BRAF fusion breakpoints 16.7 months; P < .05). Multivariate analysis confirmed their independent risk factor status for disease progression in PNOC001 and other, independent cohorts. Additionally, rare pathogenic germline variants in homologous recombination genes were identified in 6.8% of PNOC001 patients. CONCLUSION: Everolimus is a well-tolerated therapy for progressive/recurrent pLGGs. Rare/novel KIAA1549::BRAF fusion breakpoints may define biomarkers for progressive disease and should be assessed in future clinical trials.

29 February 2024 in Scientific Data
Verified
Journal Article
Open access
PDF file
DRDivya Ramakrishnan
Divya Ramakrishnan
Leon JekelLeon Jekel
Leon Jekel
SCSaahil Chadha
Saahil Chadha
AJAnastasia Janas
Anastasia Janas
HMHarrison Moy
Harrison Moy
MAMariam S. Aboian
Mariam S. Aboian
Resection and whole brain radiotherapy (WBRT) are standard treatments for brain metastases (BM) but are associated with cognitive side effects. Stereotactic radiosurgery (SRS) uses a targeted approach with less side effects than WBRT. SRS requires precise identification and delineation of BM. While artificial intelligence (AI) algorithms have been developed for this, their clinical adoption is limited due to poor model performance in the clinical setting. The limitations of algorithms are often due to the quality of datasets used for training the AI network. The purpose of this study was to create a large, heterogenous, annotated BM dataset for training and validation of AI models. We present a BM dataset of 200 patients with pretreatment T1, T1 post-contrast, T2, and FLAIR MR images. The dataset includes contrast-enhancing and necrotic 3D segmentations on T1 post-contrast and peritumoral edema 3D segmentations on FLAIR. Our dataset contains 975 contrast-enhancing lesions, many of which are sub centimeter, along with clinical and imaging information. We used a streamlined approach to database-building through a PACS-integrated segmentation workflow.

1 April 2022 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
LFLuis C. Farhat
Luis C. Farhat
EVEdoardo F.Q. Vattimo
Edoardo F.Q. Vattimo
DRDivya Ramakrishnan
Divya Ramakrishnan
JLJessica L.S. Levine
Jessica L.S. Levine
JJJessica A. Johnson
Jessica A. Johnson
MBMichael H. Bloch
Michael H. Bloch

1 January 2023 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
DRDivya Ramakrishnan
Divya Ramakrishnan
MRMarc von Reppert
Marc von Reppert
MKMark Krycia
Mark Krycia
MSMatthew Sala
Matthew Sala
SMSabine Mueller
Sabine Mueller
MAMariam S. Aboian
Mariam S. Aboian
Radiographic response assessment in neuro-oncology is critical in clinical practice and trials. Conventional criteria, such as the MacDonald and response assessment in neuro-oncology (RANO) criteria, rely on bidimensional (2D) measurements of a single tumor cross-section. Although RANO criteria are established for response assessment in clinical trials, there is a critical need to address the complexity of brain tumor treatment response with multiple new approaches being proposed. These include volumetric analysis of tumor compartments, structured MRI reporting systems like the Brain Tumor Reporting and Data System, and standardized approaches to advanced imaging techniques to distinguish tumor response from treatment effects. In this review, we discuss the strengths and limitations of different neuro-oncology response criteria and summarize current research findings on the role of novel response methods in neuro-oncology clinical trials and practice.

29 March 2024 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
DRDivya Ramakrishnan
Divya Ramakrishnan
LFLuis C. Farhat
Luis C. Farhat
EVEdoardo F.Q. Vattimo
Edoardo F.Q. Vattimo
JLJessica L.S. Levine
Jessica L.S. Levine
JJJessica A. Johnson
Jessica A. Johnson
MBMichael H. Bloch
Michael H. Bloch

27 December 2023 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
MRMarc von Reppert
Marc von Reppert
DRDivya Ramakrishnan
Divya Ramakrishnan
SBSarah C Brüningk
Sarah C Brüningk
FMFatima Memon
Fatima Memon
SFSandra Abi Fadel
Sandra Abi Fadel
MAMariam S. Aboian
Mariam S. Aboian
Although response in pediatric low-grade glioma (pLGG) includes volumetric assessment, more simplified 2D-based methods are often used in clinical trials. The study purpose was to compare volumetric to 2D methods. An expert neuroradiologist performed solid and whole tumor (including cyst and edema) volumetric measurements on MR images using a PACS-based manual segmentation tool in 43 pLGG participants (213 total follow-up images) from the PNOC-001 trial. Classification based on changes in volumetric and 2D measurements of solid tumor were compared to neuroradiologist visual response assessment using the Brain Tumor Reporting and Data System (BT-RADS) criteria for a subset of 65 images using receiver operating characteristic (ROC) analysis. Longitudinal modeling of solid tumor volume was used to predict BT-RADS classification in 54 of the 65 images. There was a significant difference in ROC area under the curve (AUC) between 3D solid tumor volume and 2D area (0.96 vs. 0.78, p = 0.005) and between 3D solid and 3D whole volume (0.96 vs. 0.84, p = 0.006) when classifying BT-RADS progressive disease (PD). Thresholds of 15-25% increase in 3D solid tumor volume had an 80% sensitivity in classifying BT-RADS PD included in their 95% confidence intervals. The longitudinal model of solid volume response had a sensitivity of 82% and positive predictive value of 67% for detecting BT-RADS PD. Volumetric analysis of solid tumor was significantly better than 2D measurements in classifying tumor progression as determined by BT-RADS criteria and will enable more comprehensive clinical management.